The goals of this proposal are to use cytogenetic and molecular biological approaches to define the genetic mechanisms of childhood brain tumors and to determine the biological significance of these findings as they relate to the initiation, etiology, progression and responsiveness to therapy of CNS tumors. Preliminary data suggests that individual types of childhood brain tumors possess specific cytogenetic and molecular genetic characteristics which are different from those seen in adult nervous system tumors. Theses studies will determine the chromosomal abnormalities of childhood brain tumors, establish cultured cell lines and transplantable xenografts which maintain these karyotypic abnormalities and use these models to determine which chromosomal regions and individual genes are altered by amplification, translocation, or deletion.
The specific aims are: 1) To define the specific chromosomal abnormalities that characterize individual types of childhood brain tumors including medulloblastomas, brainstem gliomas, ependymomas, supratentorial gliomas, and cerebellar astrocytomas in order to determine if these tumors have karyotypic profiles which are different from one another and from neuroblastomas and adult gliomas. 2) To determine the incidence of gene amplification and the spectrum of genes which are amplified in these individual types of childhood tumors. 3) To establish a bank of frozen, karyotyped childhood brain tumors and permanent cell lines and xenografts established from them to allow molecular characterization of the chromosomal abnormalities. Specifically restriction fragment length polymorphisms and in situ hybridization will be used to confirm numerical deviations and translocations and to define regions of chromosomal deletions. These studies will define the cytogenetic and molecular mechanisms which are important in the initiation and progression of childhood brain tumors and will identify subgroups of patients with similar cytogenetic or molecular genetic abnormalities whose tumors may progress more rapidly or may respond differently to specific types of therapeutic intervention. Specifically, these studies will determine if gene amplification is indicative of rapid tumor progression as has been shown for neuroblastoma. In addition, regions of chromosomes which are consistently deleted will be defined cytogenetically and molecular genetically providing the basis for the isolation and characterization of genes whose loss are central to the initiation or progression of these tumors.

Agency
National Institute of Health (NIH)
Institute
National Institute of Neurological Disorders and Stroke (NINDS)
Type
Specialized Center (P50)
Project #
2P50NS020023-06
Application #
3902040
Study Section
Project Start
Project End
Budget Start
Budget End
Support Year
6
Fiscal Year
1989
Total Cost
Indirect Cost
Name
Duke University
Department
Type
DUNS #
071723621
City
Durham
State
NC
Country
United States
Zip Code
27705
Saraswathula, Anirudh; Reap, Elizabeth A; Choi, Bryan D et al. (2016) Serum elevation of B lymphocyte stimulator does not increase regulatory B cells in glioblastoma patients undergoing immunotherapy. Cancer Immunol Immunother 65:205-11
Slastnikova, Tatiana A; Rosenkranz, Andrey A; Zalutsky, Michael R et al. (2015) Modular nanotransporters for targeted intracellular delivery of drugs: folate receptors as potential targets. Curr Pharm Des 21:1227-38
Huang, Dong-Sheng; Wang, Zhaohui; He, Xu-Jun et al. (2015) Recurrent TERT promoter mutations identified in a large-scale study of multiple tumour types are associated with increased TERT expression and telomerase activation. Eur J Cancer 51:969-76
Mitchell, Duane A; Batich, Kristen A; Gunn, Michael D et al. (2015) Tetanus toxoid and CCL3 improve dendritic cell vaccines in mice and glioblastoma patients. Nature 519:366-9
Koumarianou, Eftychia; Slastnikova, Tatiana A; Pruszynski, Marek et al. (2014) Radiolabeling and in vitro evaluation of (67)Ga-NOTA-modular nanotransporter--a potential Auger electron emitting EGFR-targeted radiotherapeutic. Nucl Med Biol 41:441-9
Choi, Bryan D; Suryadevara, Carter M; Gedeon, Patrick C et al. (2014) Intracerebral delivery of a third generation EGFRvIII-specific chimeric antigen receptor is efficacious against human glioma. J Clin Neurosci 21:189-90
Brown, Michael C; Dobrikova, Elena Y; Dobrikov, Mikhail I et al. (2014) Oncolytic polio virotherapy of cancer. Cancer 120:3277-86
Miao, Hongsheng; Choi, Bryan D; Suryadevara, Carter M et al. (2014) EGFRvIII-specific chimeric antigen receptor T cells migrate to and kill tumor deposits infiltrating the brain parenchyma in an invasive xenograft model of glioblastoma. PLoS One 9:e94281
Killela, Patrick J; Pirozzi, Christopher J; Healy, Patrick et al. (2014) Mutations in IDH1, IDH2, and in the TERT promoter define clinically distinct subgroups of adult malignant gliomas. Oncotarget 5:1515-25
Lathia, Justin D; Li, Meizhang; Sinyuk, Maksim et al. (2014) High-throughput flow cytometry screening reveals a role for junctional adhesion molecule a as a cancer stem cell maintenance factor. Cell Rep 6:117-29

Showing the most recent 10 out of 146 publications